in vitro News and Research

RSS

Cellumen's Rat Hepatocyte Early Safety Assessment Panel increases predictivity for human DILI

Cellumen, Inc., a discovery and early safety assessment company, today announced that its in vitro Rat Hepatocyte Early Safety Assessment Panel provides increased predictivity for human drug induced liver injury (DILI) equivalent to that of a recently published panel comprised of human hepatocytes. The implications of this study have a significant impact on cost and throughput for in vitro human DILI predictive solutions.

6 Nov 2009

Columbia Laboratories reports net revenues of $7.9 million for third quarter 2009

Columbia Laboratories, Inc. today reported financial results for the three- and nine-month periods ended September 30, 2009.

5 Nov 2009

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Scientists in Belgium have successfully differentiated human embryonic stem cells (hESC) into major cell types of lung epithelial tissue using a convenient air-liquid interface.

5 Nov 2009

Micro-injector may help rapid development of new generation of drugs

It's no bigger than a stamp packet but it has the potential to allow rapid development of a new generation of drugs and genetic engineering organisms, and to better control in-vitro fertilization.

5 Nov 2009

NIH grant to NC State researchers to study how nanomaterials interact with biological systems

Tiny, engineered nanomaterials can already be found in many consumer products, and have been hailed as having widespread future uses in areas ranging from medicine to industrial processes. However, little is known about what happens if these nanomaterials get into your body - where do they go? NC State researchers are working to answer that question under a grant from the National Institutes of Health (NIH).

4 Nov 2009

New improved enzyme could help facilitate spinal cord injuries

Researchers have developed an improved version of an enzyme that degrades the dense scar tissue that forms when the central nervous system is damaged. By digesting the tissue that blocks re-growth of damaged nerves, the improved enzyme - and new system for delivering it - could facilitate recovery from serious central nervous system injuries.

4 Nov 2009

H1N1 vaccine: Discussions and debates

You can't avoid H1N1 media coverage. It's front-page news on the web, the presses, the airways. Vaccine details, or lack of, are spurring discussion and debate. And a lot of people are in a quandary about whether or not to have the H1N1 shot based on their personal views and the information disseminated for public knowledge.

4 Nov 2009

Sigma-Aldrich, Polyplus-transfection sign licensing agreement to manufacture ZNA oligonucleotides

Sigma-Aldrich today announced a worldwide licensing agreement with Polyplus-transfection (Strasbourg, France) to manufacture and commercialize Zip Nucleic Acid (ZNA(TM)) oligonucleotides, a new technology that provides solutions for increased affinity for nucleic acids.

3 Nov 2009

Absorption Systems awarded FDA SBIR grant for developing its CellPort Technologies testing platform

Absorption Systems LP today announced that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant from the U.S. Food and Drug Administration (FDA) to continue development of the company’s CellPort Technologies™ testing platform. This unique assay platform enables more specific prediction of potential drug-drug interactions mediated by human drug transport proteins.

3 Nov 2009

Biomoda receives U.S patent for cytology-based screening assay

Biomoda, Inc. (OTCBB: BMOD), an Albuquerque-based cancer diagnostics company, announces that it has received notice of allowance for a U.S. Patent protecting the proprietary formula for the composition that binds to cancer cells which is utilized in Biomoda’s screening assay for the early detection of cancer

3 Nov 2009

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for its Aurora A/angiogenic kinase inhibitor, ENMD-2076, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held November 15-19, 2009 in Boston, Massachusetts. Presentations are listed below.

3 Nov 2009

Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms

Texas State University and Orizon Research Institute announced the signing of an agreement today that will permit University Researchers to continue efforts through in vivo testing to further determine the potential and effectiveness of ALKA-V6, a compound which has shown remarkable ability to kill cancer cells and inhibit the HIV virus in laboratory experiments.

3 Nov 2009

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor.

3 Nov 2009

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.

2 Nov 2009

Nuevolution receives milestone payment from Merck

Nuevolution A/S today announced that it has received a milestone payment derived from its collaboration with Merck & Co. Inc., Whitehouse Station, NJ.

2 Nov 2009

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.

31 Oct 2009

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

Idenix Pharmaceuticals, Inc.a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) currently being held in Boston, Massachusetts.

30 Oct 2009

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA.

30 Oct 2009

Researchers use BEZ235 drug to eliminate NSCL cancer

Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.

30 Oct 2009

AAPS workshop on drug release methodologies

AAPS is pleased to present the workshop on Special Dosage Forms - What's New with In Vitro Drug Release? This event will present drug release methodologies to evaluate the product performance for special dosage forms and provide opportunities for the participants to interact with the faculty in panel discussions.

29 Oct 2009

in vitro News and Research

Cellumen's Rat Hepatocyte Early Safety Assessment Panel increases predictivity for human DILI

Columbia Laboratories reports net revenues of $7.9 million for third quarter 2009

Scientists differentiate human embryonic stem cells into lung epithelial tissue using air-liquid interface

Micro-injector may help rapid development of new generation of drugs

NIH grant to NC State researchers to study how nanomaterials interact with biological systems

New improved enzyme could help facilitate spinal cord injuries

H1N1 vaccine: Discussions and debates

Sigma-Aldrich, Polyplus-transfection sign licensing agreement to manufacture ZNA oligonucleotides

Absorption Systems awarded FDA SBIR grant for developing its CellPort Technologies testing platform

Biomoda receives U.S patent for cytology-based screening assay

EntreMed to present its Aurora A/angiogenic kinase inhibitor data at the AACR-NCI-EORTC conference

Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

Avila Therapeutics presents preclinical study data of its AVL-181 HCV protease inhibitor

Nuevolution receives milestone payment from Merck

NovaBay Pharmaceuticals' Aganocide compounds demonstrate potent antifungal activity against onychomycosis

Idenix Pharmaceuticals reports phase I study results of IDX184 for treating HCV

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Researchers use BEZ235 drug to eliminate NSCL cancer

AAPS workshop on drug release methodologies

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News